Investors purchased shares of Intrexon Corp (NYSE:XON) on weakness during trading hours on Thursday. $47.67 million flowed into the stock on the tick-up and $6.74 million flowed out of the stock on the tick-down, for a money net flow of $40.93 million into the stock. Of all equities tracked, Intrexon had the 23rd highest net in-flow for the day. Intrexon traded down ($0.33) for the day and closed at $4.11

A number of brokerages have issued reports on XON. JMP Securities reissued a “buy” rating and issued a $43.00 price target on shares of Intrexon in a report on Wednesday, March 6th. Zacks Investment Research upgraded shares of Intrexon from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research note on Saturday, January 19th. Finally, Northland Securities lowered shares of Intrexon from an “outperform” rating to a “market perform” rating in a research report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $34.00.

In related news, insider Thomas D. Reed sold 225,500 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $4.18, for a total transaction of $942,590.00. Following the transaction, the insider now owns 96,280 shares of the company’s stock, valued at $402,450.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Randal J. Kirk sold 95,241 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $0.65, for a total value of $61,906.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 362,419 shares of company stock worth $1,032,421. Insiders own 48.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sanders Morris Harris LLC grew its stake in shares of Intrexon by 22.3% in the first quarter. Sanders Morris Harris LLC now owns 222,809 shares of the biotechnology company’s stock valued at $1,172,000 after buying an additional 40,609 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Intrexon in the 1st quarter worth $169,000. Truvestments Capital LLC acquired a new position in shares of Intrexon in the 1st quarter worth $32,000. Valeo Financial Advisors LLC grew its holdings in shares of Intrexon by 60.9% during the first quarter. Valeo Financial Advisors LLC now owns 10,569 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 4,000 shares in the last quarter. Finally, Addison Capital Co purchased a new position in shares of Intrexon during the first quarter valued at $81,000. Hedge funds and other institutional investors own 84.92% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Traders Buy Shares of Intrexon (XON) on Weakness” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2019/04/20/traders-buy-shares-of-intrexon-xon-on-weakness.html.

Intrexon Company Profile (NYSE:XON)

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Story: Balanced Fund

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.